You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

antibodies, monoclonal, humanized

Showing 1 - 25 of 8,652
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Gout Trial in Wuhan, Linyi, Shanghai (Recombinant Anti-IL-1ß Humanized Monoclonal Antibody Injection 100 mg (phase Ib),

Recruiting
  • Acute Gout
  • Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)
  • +6 more
  • Wuhan, Hubei, China
  • +2 more
Oct 17, 2022

Psoriasis Trial in Shanghai, Kunming (Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection, Placebo)

Active, not recruiting
  • Psoriasis
  • Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
  • Placebo
  • Shanghai, Shanghai, China
  • +2 more
Nov 7, 2022

Healthy Trial in Qingdao (VDJ001, Placebo)

Completed
  • Healthy
  • Qingdao, Shandong, China
    the Affliated Hospital of Qingdao University
Aug 30, 2023

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell Trial in Najing (Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Lymphoma, T-Cell
  • Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection
  • Najing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Sep 26, 2022

Ovarian Cancer Trial in New York (90Y-hu3S193, 111In-hu3S193)

Completed
Has Results
  • Ovarian Cancer
  • 90Y-hu3S193
  • 111In-hu3S193
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Atopic Dermatitis Trial in Shanghai (MG-K10/Placebo)

Active, not recruiting
  • Atopic Dermatitis
  • MG-K10/Placebo
  • Shanghai, China
    Huashan Hospital Affiliated to Fudan University
Aug 31, 2023

Advanced Solid Tumor Trial in Bengbu (HB0030 injection)

Recruiting
  • Advanced Solid Tumor
  • HB0030 injection
  • Bengbu, Anhui, China
    the First Affiliated Hospital of Bengbu Medical College
Jan 20, 2023

Ebola Virus Disease Trial in Sankt-Peterburg (Gamezumab)

Recruiting
  • Ebola Virus Disease
  • Sankt-Peterburg, Russian Federation
    Research Institute of Influenza
Feb 17, 2021

Recurrent Osteosarcoma Trial in Los Angeles, New York, Houston (humanized anti-GD2 antibody, GM-CSF)

Recruiting
  • Recurrent Osteosarcoma
  • humanized anti-GD2 antibody
  • GM-CSF
  • Los Angeles, California
  • +2 more
Dec 22, 2022

Advanced Solid Tumors Trial in Shanghai (HLX07+Gemcitabine+Cisplatin, HLX07+Paclitaxel+Carboplatin, HLX07+mFOLFOX6)

Active, not recruiting
  • Advanced Solid Tumors
  • Shanghai, Shanghai, China
    Shanghai East Hospital
May 5, 2022

NSCLC Stage IV Trial (HLX26, Serplulimab, Pemetrexed)

Not yet recruiting
  • NSCLC Stage IV
  • (no location specified)
Mar 15, 2023

Ovarian Cancer Trial in New York (Monoclonal antibody hu3S193)

Terminated
Has Results
  • Ovarian Cancer
  • Monoclonal antibody hu3S193
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Idiopathic Multicentric Castleman's Disease Trial in Beijing, Chengdu (Recombinant Humanized Anti-interleukin-6 Receptor

Recruiting
  • Idiopathic Multicentric Castleman's Disease
  • Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg
  • +2 more
  • Beijing, China
  • +2 more
Apr 26, 2022

Alzheimer Trial (Lecanemab)

Not yet recruiting
  • Alzheimer Disease
  • (no location specified)
Jun 22, 2023

Cancer of Unknown Primary Trial in Shanghai (Recombinant humanized anti-PD-1 mAb injection)

Recruiting
  • Cancer of Unknown Primary
  • Recombinant humanized anti-PD-1 monoclonal antibody injection
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 18, 2022

B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in China (Orelabrutinib, Recombinant humanized mAb MIL62 injection)

Active, not recruiting
  • B-cell Lymphoma Recurrent
  • B-cell Lymphoma Refractory
  • Orelabrutinib
  • Recombinant humanized monoclonal antibody MIL62 injection
  • Bengbu, Anhui, China
  • +9 more
Nov 11, 2022

Medicare Anti-Aß mAb Coverage With Evidence Development Study

Recruiting
  • Mild Alzheimer's Disease
  • Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
  • Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
  • Baltimore, Maryland
    Centers for Medicare and Medicaid Services
Sep 21, 2023

Colorectal Cancer Trial in New York (mAb hu3S193)

Terminated
Has Results
  • Colorectal Cancer
  • monoclonal antibody hu3S193
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Covid-19 Convalescent Plasma and Monoclonal Antibodies Treatment

Recruiting
  • COVID-19 Convalescent Plasma Treatment
    • Strasbourg, France
      Service des Maladies Infectieuses et Tropicales - CHU de Strasbo
    Jun 15, 2023

    Primary Membranous Nephropathy Trial in Beijing (B007)

    Not yet recruiting
    • Primary Membranous Nephropathy
    • Beijing, China
      Peking university first hospital
    Dec 20, 2022

    Clostridium Infection Trial in Paris (Collection of peripheral blood mononuclear cells)

    Completed
    • Clostridium Infection
    • Collection of peripheral blood mononuclear cells
    • Paris, France
      Maladies infectieuses et tropicales, Hôpital Pitié-Salpêtrière
    Oct 3, 2022

    Asthma Trial in Guangzhou (MG-K10, Placebo)

    Recruiting
    • Asthma
    • Guangzhou, Guangdong, China
      The First Affiliated Hospital of Guangzhou Medical University
    Jul 13, 2022

    Psoriasis Trial in Shanghai (608 Q2W, 608 Q4W, Placebo)

    Not yet recruiting
    • Psoriasis
    • 608 Q2W
    • +2 more
    • Shanghai, Shanghai, China
      Shanghai Huanshan Hospital Fudan University
    Sep 8, 2022

    Solid Tumor, Adult Trial in Minneapolis, Hackensack, Houston (FT516, Avelumab, Cyclophosphamide)

    Completed
    • Solid Tumor, Adult
    • Minneapolis, Minnesota
    • +2 more
    Jan 27, 2023

    Sarcoma, Soft Tissue Trial in Beijing (Recombinant anti-PD-1 humanized mAb injection)

    Not yet recruiting
    • Sarcoma, Soft Tissue
    • Recombinant anti-PD-1 humanized monoclonal antibody injection
    • Beijing, Beijing, China
      Beijing Jishuitan Hospital
    Dec 31, 2021